These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22926573)

  • 1. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
    Lechartier B; Hartkoorn RC; Cole ST
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5790-3. PubMed ID: 22926573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207.
    Reddy VM; Einck L; Andries K; Nacy CA
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2840-6. PubMed ID: 20385864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
    Sala C; Dhar N; Hartkoorn RC; Zhang M; Ha YH; Schneider P; Cole ST
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4150-8. PubMed ID: 20679505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis.
    Chan CY; Au-Yeang C; Yew WW; Leung CC; Cheng AF
    Antimicrob Agents Chemother; 2004 Jan; 48(1):340-3. PubMed ID: 14693563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.
    Wallis RS; Jakubiec W; Mitton-Fry M; Ladutko L; Campbell S; Paige D; Silvia A; Miller PF
    PLoS One; 2012; 7(1):e30479. PubMed ID: 22279595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
    Makarov V; Manina G; Mikusova K; Möllmann U; Ryabova O; Saint-Joanis B; Dhar N; Pasca MR; Buroni S; Lucarelli AP; Milano A; De Rossi E; Belanova M; Bobovska A; Dianiskova P; Kordulakova J; Sala C; Fullam E; Schneider P; McKinney JD; Brodin P; Christophe T; Waddell S; Butcher P; Albrethsen J; Rosenkrands I; Brosch R; Nandi V; Bharath S; Gaonkar S; Shandil RK; Balasubramanian V; Balganesh T; Tyagi S; Grosset J; Riccardi G; Cole ST
    Science; 2009 May; 324(5928):801-4. PubMed ID: 19299584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.
    Makarov V; Neres J; Hartkoorn RC; Ryabova OB; Kazakova E; Šarkan M; Huszár S; Piton J; Kolly GS; Vocat A; Conroy TM; Mikušová K; Cole ST
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4446-52. PubMed ID: 25987616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.
    Pasca MR; Degiacomi G; Ribeiro AL; Zara F; De Mori P; Heym B; Mirrione M; Brerra R; Pagani L; Pucillo L; Troupioti P; Makarov V; Cole ST; Riccardi G
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1616-8. PubMed ID: 20086151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
    Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis.
    Grover S; Alderwick LJ; Mishra AK; Krumbach K; Marienhagen J; Eggeling L; Bhatt A; Besra GS
    J Biol Chem; 2014 Feb; 289(9):6177-87. PubMed ID: 24446451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis.
    Sulochana S; Mitchison DA; Kubendiren G; Venkatesan P; Paramasivan CN
    J Chemother; 2009 Apr; 21(2):127-34. PubMed ID: 19423464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tuberculosis: clinical trials and new drug regimens.
    Kwon YS; Jeong BH; Koh WJ
    Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
    Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
    Chen P; Gearhart J; Protopopova M; Einck L; Nacy CA
    J Antimicrob Chemother; 2006 Aug; 58(2):332-7. PubMed ID: 16751637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
    De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
    J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a new combination therapy for tuberculosis with next generation benzothiazinones.
    Makarov V; Lechartier B; Zhang M; Neres J; van der Sar AM; Raadsen SA; Hartkoorn RC; Ryabova OB; Vocat A; Decosterd LA; Widmer N; Buclin T; Bitter W; Andries K; Pojer F; Dyson PJ; Cole ST
    EMBO Mol Med; 2014 Mar; 6(3):372-83. PubMed ID: 24500695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis.
    Ge F; Zeng F; Liu S; Guo N; Ye H; Song Y; Fan J; Wu X; Wang X; Deng X; Jin Q; Yu L
    J Med Microbiol; 2010 May; 59(Pt 5):567-572. PubMed ID: 20075118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of a microcalorimetric method for determining drug susceptibility in mycobacterium species.
    Howell M; Wirz D; Daniels AU; Braissant O
    J Clin Microbiol; 2012 Jan; 50(1):16-20. PubMed ID: 22090404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model.
    Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A
    mBio; 2010 Aug; 1(3):. PubMed ID: 20802826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.